武汉地区34家医院2011－2013年口服降糖药应用分析

摘要

目的：了解口服降糖药在武汉地区的应用情况和变化趋势，为临床选择用药和企业产销提供参考。方法：对武汉地区34家医院2011－2013年口服降糖药的销售金额、用药频度、日均费用等数据进行统计分析。结果：口服降糖药销售总额和用药频度分别以超过20％和7％的增长率逐年升高。阿卡波糖占有近四成市场份额，二甲双胍使用频率仅次于阿卡波糖。二肽基肽酶抑制剂前景可观，销售金额所占比重超过10％。中药类市场份额跌破3％。除了瑞格列奈、格列齐特、格列美脲、消渴丸等，其他药物销售情况和用药人群相一致。结论：武汉地区34家医院2011－2013年口服降糖药的应用基本合理。%OBJECTIVE:To analyze the utilization and variation tendency of oral hypoglycemic agents in Wuhan area,and to provide reference for drug selection and enterprise production and sale. METHODS:The utilization of oral hypoglycemic agents in 34 hospitals from Wuhan area during 2011-2013 was analyzed statistically in respects of consumption sum,DDDs and DDC etc. RESULTS:The consumption sum and DDDs of oral hypoglycemic agents increased by 20% and 7% respectively year by year. Acarbose had a market share of over 40%. The drug use frequency of metformin ranked the second place only to acarbose. DPP-4 inhibitor had a promising future,with a consumption sum proportion of more than 10%,while the market share of traditional Chi-nese medicine had fallen below 3%. Except for repaglinide,gliclazide,glimepiride,Xiaoke pills,etc.,the selling of other medica-tions are consistent with the user. CONCLUSIONS:The utilization of oral hypoglycemic drugs is basically rational in 34 hospitals from Wuhan area during 2011-2013.